Nicolas Veziris

Latest

• Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement
• Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
• Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe